WJ10

WJ10 is a small molecule oncology candidate currently in development by Wigen Biomedicine Technology (Shanghai). As of recent pipeline updates, the specific molecular target of WJ10 remains undisclosed, although it is categorized within the company's oncology portfolio. Wigen Biomedicine focuses on developing highly selective small molecule inhibitors for challenging targets in cancer, such as KRAS, USP1, and SOS1. WJ10 represents an early-stage asset in this pipeline, potentially addressing unmet needs in solid tumors. While some early reports and industry databases have previously associated the code WJ10 with targets like KRAS G12C or USP1, these targets are now linked to other specific clinical-stage codes (WJ01024 and WJ07107, respectively) in the company's current pipeline, where WJ10 remains a distinct, undisclosed entry.